Please complete the CAPTCHA to continue
@sbcglobal.net
✓
1 phone found area 650
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Nigel Ray is listed as President and CEO at Angarus Therapeutics, Inc. at Angarus Therapeutics, Inc., based in South San Francisco, California, United States. AeroLeads shows a work email signal at sbcglobal.net, phone signal with area code 650, and a matched LinkedIn profile for Nigel Ray.
Nigel Ray previously worked as President and CEO at Angarus Therapeutics, Inc. and President and CEO/COO at Tolerion, Inc.. Nigel Ray holds Mba, Business, Finance from Ucla Anderson School Of Management.
This section adds company-level context without repeating Nigel Ray's masked contact details.
AeroLeads found 1 current-domain work email signal for Nigel Ray. Compare company email patterns before reaching out.
A business development and marketing professional with over 25 years in specialty pharmaceuticals. Combines strong business acumen with scientific and technical savvy. Track record of success identifying, structuring and negotiating complex, worldwide pharmaceutical product and technology licensing transactions. Scientific research experience, plus MBA and biology BA from top tier schools. Industry expertise includes P&L responsibility, alliance management and both buy- and sell-side deal making.Specialties: Licensing (both buy and sell side)NegotiationMarketingBusiness DevelopmentNew Product PlanningMarket Evaluations
Listed skills include Pharmaceutical Industry, Biotechnology, Business Development, Licensing, and 11 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Checkpoint inhibitors have transformed cancer treatment by enhancing patients’ existing anti-tumor immune responses, but this approach does not work in the vast majority of immunologically “cold” tumors where there is no underlying immune response to amplify. Angarus is developing small molecule checkpoint inhibitors that can initiate cytotoxic T-cell.
Tolerion is a clinical stage biotechnology company developing TOL-3021, which has potential to be the first disease modifying therapeutic for type-1 diabetes (T1D) and the first significant innovation in the treatment of this autoimmune disease since the discovery of insulin some 70 years ago. TOL-3021 is designed to restore antigen-specific tolerance in.
South San Francisco, CA, US
Atreca is a privately held immuno-oncology company with a platform for identifying novel antibodies and tumor targets which drive successful treatment outcomes. We measure and analyze the structure of patients’ clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Using.
Lawrenceville, New Jersey, US
Responsible for creating and implementing an effective, proactive growth strategy for Aptalis’s licensing business and for leading a team of 8 licensing professionals in both US and Europe that identify and evaluate new opportunities and structure relationships with pharmaceutical companies globally, maximizing the values of Aptalis’s technologies and.
San Mateo, California, US
Led the licensing of 3 clinical-stage products to treat post-operative pain, cancer breakthrough pain and procedural analgesia/sedation. Developed worldwide and regional licensing strategies and managed all aspects of licensing discussions with partners.
US
Established business development strategy and led Limerick BioPharma’s partnering efforts for select early-stage assets in pain, immunosuppression and metabolic disease
Identified, structured and negoted complex, worldwide product and technology licensing transactions with pharmaceutical and biotechnology partners. Led the licensing for ELADUR, a transdermal pain product in Phase 2. Managed all aspects of licensing discussions with potential partners, including managing 11 large and specialty pharmaceutical partners.
Built and managed a profitable commercial business unit of ALZA Pharmaceuticals with worldwide sales. Accountable for P&L performance to ALZA’s V.P. of Marketing and Sales. Consistently exceeded sales growth and profit contribution targets.
Quick answers generated from the profile data available on this page.
Nigel Ray works for Angarus Therapeutics, Inc..
Nigel Ray is listed as President and CEO at Angarus Therapeutics, Inc. at Angarus Therapeutics, Inc..
AeroLeads has found 1 work email signal at @sbcglobal.net for Nigel Ray at Angarus Therapeutics, Inc..
AeroLeads has found 1 phone signal(s) with area code 650 for Nigel Ray at Angarus Therapeutics, Inc..
Nigel Ray is based in South San Francisco, California, United States while working with Angarus Therapeutics, Inc..
Nigel Ray has worked for Angarus Therapeutics, Inc., Tolerion, Inc., Atreca, Inc., Aptalis, and Acelrx Pharmaceuticals, Inc..
You can use AeroLeads to view verified contact signals for Nigel Ray at Angarus Therapeutics, Inc., including work email, phone, and LinkedIn data when available.
Nigel Ray holds Mba, Business, Finance from Ucla Anderson School Of Management.
Nigel Ray is listed with skills including Pharmaceutical Industry, Biotechnology, Business Development, Licensing, Drug Development, Technology Transfer, Strategic Alliances, and Marketing.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts